Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SFA005
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : SFA Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Melior Discovery Announces Partnership with SFA on Grant Directed to COVID-19
Details : In this important effort to counter the effects of the COVID-19 virus SFA005 is expected to address the cytokine storm linked to Acute Respiratory Distress Syndrome (ARDS) experienced by patients infected with COVID-19.
Brand Name : SFA005
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
June 24, 2020
Lead Product(s) : SFA005
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : SFA Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
LOOKING FOR A SUPPLIER?